Table 4.
Clinical and molecular features of patients with HER2 alterations treated with anti-targeted therapy.
| PatientID | Gender | Histology | Tumor stage | Age at diagnosis | Therapy line | anti-HER2 therapy | Best Response | PFS, m | Pre-tx HER2 alteration | Pre-tx sample type | Post-tx sample type | Panel |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P01 | Male | Ad | IV | 55 | 3 | Pyrotinib | PR | 6.8 | Exon 20 ins (exact sequence unknown) |
T | NA | – |
| P02 | Male | Ad | III | 52 | 2 | Pyrotinib | PR | 3.7 | p.Y772_A775dup, amp | B | NA | – |
| P03 | Female | Ad | IV | 55 | 2 | Pyrotinib | SD | 2.4 | p.G779_P780dup | T | NA | – |
| P04 | Male | Ad | IV | 61 | 2 | Pyrotinib | PR | 6.3 (ongoing) | Exact sequence unknown |
– | NA | – |
| P05 | Female | Ad | IV | 56 | 3 | Pyrotinib | SD | 4 | Exon 20 ins (exact sequence unknown) |
H | NA | – |
| P06 | Female | Ad | IV | 50 | 3 | Pyrotinib | SD | 4.9 | Exon 20 ins (exact sequence unknown) |
B | NA | – |
| P07 | Male | Ad | IV | 63 | 2/3 | Pyrotinib/Pyrotinib | SD/SD | 3.5/2.8 | p.Y772_A775dup | T | NA | – |
| P08 | Female | Ad | IV | 60 | 2/3 | Pyrotinib/Pyrotinib | SD/SD | 10.2/4.9 | p.Y772_A775dup | T | NA | – |
| P09 | Female | Ad | IV | 76 | 1 | Pyrotinib | SD | 12.2 | p.Y772_A775dup | – | NA | – |
| P10 | Male | Ad | III | 50 | 1 | Pyrotinib | CR | 33.3 (ongoing) | p.S310X (exact sequence unknown), amp | – | NA | – |
| P11 | Male | Ad | I | 71 | 1 | Pyrotinib | SD | 9.5 | Amp | T | NA | – |
| P12 | Male | Ad | IV | 62 | 1 | Pyrotinib | PD | 2.2 | p.Y772_A775dup | T | B | 1021 |
| P13 | Male | Ad | IV | 57 | 1 | Afatinib | PR | 4 | p.Y772_A775dup | T | T | 1021 |
| P14 | Female | Ad | – | 56 | 3 | Afatinib | SD | 2 | p.G778_P780dup | T | T | 59 |
| P15 | Female | LCLC | IV | 53 | 3 | Afatinib | – | 6 | p.V659E | T | B | 1021 |
| P16 | Female | Ad | IV | 48 | 4 | Pyrotinib | – | 5 | p.Y772_A775dup | C | C | 1021 |
| P17 | Female | Ad | IV | 62 | 2 | Afatinib | PD | 7.8 | p.G778_P780dup | H | H | 1021 |
| P18 | Male | Ad | IV | 52 | 5 | Afatinib | PD | 1 | Amp | T | B | 59 |
| P19 | Male | Ad | IV | 63 | 1 | Afatinib | – | 5 | p.Y772_A775dup | B | B | 1021 |
| P20 | Male | Ad | IV | 39 | 2 | Afatinib | PD | 3 | p.Y772_A775dup | T | B | 1021 |
| P21 | Female | Ad | IV | 60 | 4 | Pyrotinib | – | 14 | p.Y772_A775dup | T | B | 1,021 |
Ad, adenocarcinoma; LCLC, large cell lung cancer; T, tissue; H, hydrothorax; B, blood; C, cerebrospinal fluid; –, data not available; NA, not applicable.